Dare Bioscience vs Ovid Therapeutics
Ovid Therapeutics is the larger business, with $7.3m of revenue in fiscal 2025 against $1.0m for Dare Bioscience (7.0 times as much). Dare Bioscience grew faster (10429.4% against 1181.3%). Ovid Therapeutics kept more of each dollar of sales as profit: a net margin of -240.1% against -1300.7%. Dare Bioscience carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Dare BioscienceDARE, 2025 | Ovid TherapeuticsOVID, 2025 |
|---|---|---|
| Revenue | $1.0m | $7.3m |
| Revenue growth | 10429.4% | 1181.3% |
| Net income | −$13.4m | −$17.4m |
| Operating margin | -1315.5% | -585.2% |
| Net margin | -1300.7% | -240.1% |
| Return on equity | — | -17.5% |
| Free cash flow | −$10.3m | −$38.3m |
| Cash | $24.7m | $13.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 24 | 23 |
| Market value | $9.7m | $446m |
| Price vs our value range | — | — |
| Moat score | — | 10 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 2 sales |